NASDAQ: OMOutset Medical Inc Stock
$2.38-0.17 (-6.67%)
Updated Apr 25, 2024
OM Price
$2.38
Fair Value Price
$3.30
Market Cap
$120.20M
52 Week Low
$1.92
52 Week High
$24.13
P/E
-0.68x
P/B
0.98x
P/S
2.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$130.38M
Earnings
-$172.80M
Gross Margin
22.2%
Operating Margin
-122.41%
Profit Margin
-132.5%
Debt to Equity
1.55
Operating Cash Flow
-$131M
Beta
1.51
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OM Overview
Outset Medical, Inc. offers the Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and cloud-connected software and connectivity capabilities used for dialysis care in acute and home settings. Formerly Home Dialysis Plus, Ltd., Outset Medical was incorporated in 2003 and is headquartered in San Jose, CA.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OM ($2.38) is undervalued by 27.95% relative to our estimate of its Fair Value price of $3.30 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
OM ($2.38) is significantly undervalued by 27.95% relative to our estimate of its Fair Value price of $3.30 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
OM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OM due diligence checks available for Premium users.
Be the first to know about important OM news, forecast changes, insider trades & much more!
OM News
Valuation
OM fair value
Fair Value of OM stock based on Discounted Cash Flow (DCF)
Price
$2.38
Fair Value
$3.30
Undervalued by
27.95%
OM ($2.38) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OM ($2.38) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.68x
Industry
29.73x
Market
40.97x
OM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.98x
Industry
3.71x
OM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OM's financial health
Profit margin
Revenue
$30.5M
Net Income
-$38.6M
Profit Margin
-126.5%
OM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
OM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$313.8M
Liabilities
$190.9M
Debt to equity
1.55
OM's short-term assets ($291.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OM's short-term assets ($291.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.4M
Investing
$23.4M
Financing
$33.2M
OM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OM vs Medical Device Stocks
Outset Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.